A novel drug candidate (TGR63) developed for the treatment of Alzheimer’s disease

Prof. T. Govindaraju and his research team has developed a novel drug candidate (TGR63) for the treatment of Alzheimer’s disease

TGR63 treatment significantly reduce cortical and hippocampal amyloid burden by disrupting the salt bridges and intermolecular hydrogen bonding interactions within amyloid fibrils, in the progressive stages of APP/PS1 AD mice brain. Various behavioural tests demonstrated the reversal of cognitive decline. The excellent biocompatibility, blood-brain-barrier (BBB) permeability, and therapeutic efficacy to reduce amyloid burden and rescue of cognitive decline in AD mice model revealed that TGR63 a promising candidate for the treatment of AD.


Read more: 

Samanta, S., Rajasekhar, K., Ramesh, M., Murugan, N.A., Alam, S., Shah, D., Clement, J.P. and Govindaraju, T. (2021), Naphthalene Monoimide Derivative Ameliorates Amyloid Burden and Cognitive Decline in a Transgenic Mouse Model of Alzheimer's Disease. Adv. Therap. 2000225. https://doi.org/10.1002/adtp.202000225

Supporting video 1, 2, 3




Posted By Webmaster(JNCASR)@ 15-02-2021

Research Units


Dean Offices &

Administrative Units


Academic Programmes


Information for Visitors


JNC Quick Links


Search Person

Jncasr News